Kassondra Meyer

492 total citations
14 papers, 355 citations indexed

About

Kassondra Meyer is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Kassondra Meyer has authored 14 papers receiving a total of 355 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Kassondra Meyer's work include PARP inhibition in cancer therapy (5 papers), BRCA gene mutations in cancer (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Kassondra Meyer is often cited by papers focused on PARP inhibition in cancer therapy (5 papers), BRCA gene mutations in cancer (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Kassondra Meyer collaborates with scholars based in United States, United Kingdom and South Korea. Kassondra Meyer's co-authors include Susan M. Domchek, Helen K. Angell, Michelle Ferguson, Yvette Drew, Pia Herbolsheimer, Maja J.A. de Jonge, Sook Hee Hong, Y.H. Park, Ricardo H. Álvarez and Mark C. Lanasa and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Molecular and Cellular Biology.

In The Last Decade

Kassondra Meyer

14 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kassondra Meyer United States 9 269 128 123 96 32 14 355
Lorena Fariñas-Madrid Spain 8 205 0.8× 102 0.8× 91 0.7× 40 0.4× 24 0.8× 24 280
E. Hitt Nichols United States 3 231 0.9× 91 0.7× 83 0.7× 96 1.0× 9 0.3× 5 267
Esther Schoutrop Sweden 7 170 0.6× 39 0.3× 69 0.6× 114 1.2× 20 0.6× 8 274
Irene Ekwede United States 9 273 1.0× 68 0.5× 139 1.1× 67 0.7× 6 0.2× 25 360
Heather Derocher Canada 6 288 1.1× 50 0.4× 65 0.5× 196 2.0× 19 0.6× 6 406
Paulo Mora United States 5 203 0.8× 137 1.1× 73 0.6× 27 0.3× 17 0.5× 6 251
Iulia Cirlan Canada 2 90 0.3× 52 0.4× 138 1.1× 58 0.6× 11 0.3× 3 246
Jinxiao Liang China 10 83 0.3× 35 0.3× 218 1.8× 39 0.4× 4 0.1× 27 330
Ravi Chauhan India 8 148 0.6× 12 0.1× 149 1.2× 55 0.6× 11 0.3× 19 318
Maud Jonnaert United States 6 99 0.4× 88 0.7× 122 1.0× 146 1.5× 11 0.3× 8 321

Countries citing papers authored by Kassondra Meyer

Since Specialization
Citations

This map shows the geographic impact of Kassondra Meyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kassondra Meyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kassondra Meyer more than expected).

Fields of papers citing papers by Kassondra Meyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kassondra Meyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kassondra Meyer. The network helps show where Kassondra Meyer may publish in the future.

Co-authorship network of co-authors of Kassondra Meyer

This figure shows the co-authorship network connecting the top 25 collaborators of Kassondra Meyer. A scholar is included among the top collaborators of Kassondra Meyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kassondra Meyer. Kassondra Meyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Krebs, Matthew, Jean‐Pierre Delord, T.R. Jeffry Evans, et al.. (2023). Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. Lung Cancer. 180. 107216–107216. 27 indexed citations
2.
3.
4.
Drew, Yvette, Bella Kaufman, Susana Banerjee, et al.. (2019). Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC). Annals of Oncology. 30. v485–v486. 80 indexed citations
5.
Drew, Yvette, Maja J.A. de Jonge, Sook Hee Hong, et al.. (2018). An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA -mutated ( gBRCA m) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecologic Oncology. 149. 246–247. 111 indexed citations
6.
Penson, Richard T., Yvette Drew, Maja J.A. de Jonge, et al.. (2018). MEDIOLA: A phase I/II trial of olaparib (PARP inhibitor) in combination with durvalumab (anti-PD-L1 antibody) in pts with advanced solid tumours – new ovarian cancer cohorts. Annals of Oncology. 29. viii147–viii147. 8 indexed citations
7.
Meyer, Kassondra, Brittany N. Albaugh, Barry Schoenike, & Avtar Roopra. (2015). Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST. Molecular and Cellular Biology. 35(17). 2991–3004. 9 indexed citations
8.
Grossi, Francesco, Carlo Genova, Erika Rijavec, et al.. (2014). Serum Mass-Spectrometry Test in First Line Advanced Nsclc Patients Treated with Standard Chemotherapy Regimens. Annals of Oncology. 25. iv463–iv463. 1 indexed citations
9.
Zomak, R., Kassondra Meyer, Christian Bermudez, et al.. (2013). Pattern and Predictors of Hospital Readmission after Lung Transplantation. The Journal of Heart and Lung Transplantation. 32(4). S44–S44. 1 indexed citations
10.
Gunsalus, Kearney T. W., Matthew P. Wagoner, Kassondra Meyer, et al.. (2012). Induction of the RNA Regulator LIN28A Is Required for the Growth and Pathogenesis of RESTless Breast Tumors. Cancer Research. 72(13). 3207–3216. 13 indexed citations
11.
Squirrell, Jayne M., Kassondra Meyer, Nirupama K. Shevde, et al.. (2012). Endogenous Fluorescence Signatures in Living Pluripotent Stem Cells Change with Loss of Potency. PLoS ONE. 7(8). e43708–e43708. 16 indexed citations
12.
Love, Robert B., et al.. (2003). Ten year experience with human lung transplantation from non-heart beating donors. The Journal of Heart and Lung Transplantation. 22(1). S87–S87. 20 indexed citations
13.
Schlaifer, D, Kassondra Meyer, C. Müller, et al.. (1994). Antisense inhibition of myeloperoxidase increases the sensitivity of the HL-60 cell line to vincristine.. PubMed. 8(2). 289–91. 14 indexed citations
14.
Meyer, Kassondra. (1955). [Idiopathic lung hemosiderosis].. PubMed. 10(25). 583–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lorena Fariñas-Madrid Breakdown of academic impact, for papers by E. Hitt Nichols Breakdown of academic impact, for papers by Esther Schoutrop Breakdown of academic impact, for papers by Irene Ekwede Breakdown of academic impact, for papers by Heather Derocher Breakdown of academic impact, for papers by Paulo Mora Breakdown of academic impact, for papers by Iulia Cirlan Breakdown of academic impact, for papers by Jinxiao Liang Breakdown of academic impact, for papers by Ravi Chauhan Breakdown of academic impact, for papers by Maud Jonnaert
Rankless by CCL
2026